Kvik ||| S:0 E:4 ||| NNP
:  ||| S:4 E:6 ||| :
three-tier  ||| S:6 E:17 ||| JJ
data  ||| S:17 E:22 ||| NN
exploration  ||| S:22 E:34 ||| NN
tools  ||| S:34 E:40 ||| NNS
for  ||| S:40 E:44 ||| IN
flexible  ||| S:44 E:53 ||| JJ
analysis  ||| S:53 E:62 ||| NN
of  ||| S:62 E:65 ||| IN
genomic  ||| S:65 E:73 ||| JJ
data  ||| S:73 E:78 ||| NNS
in  ||| S:78 E:81 ||| IN
epidemiological  ||| S:81 E:97 ||| JJ
studies  ||| S:97 E:105 ||| NNS
Kvik  ||| S:105 E:110 ||| NNP
is  ||| S:110 E:113 ||| VBZ
an  ||| S:113 E:116 ||| DT
open-source  ||| S:116 E:128 ||| JJ
framework  ||| S:128 E:138 ||| NN
that  ||| S:138 E:143 ||| IN
we  ||| S:143 E:146 ||| PRP
developed  ||| S:146 E:156 ||| VBD
for  ||| S:156 E:160 ||| IN
explorative  ||| S:160 E:172 ||| JJ
analysis  ||| S:172 E:181 ||| NN
of  ||| S:181 E:184 ||| IN
functional  ||| S:184 E:195 ||| JJ
genomics  ||| S:195 E:204 ||| JJ
data  ||| S:204 E:209 ||| NNS
from  ||| S:209 E:214 ||| IN
large  ||| S:214 E:220 ||| JJ
epidemiological  ||| S:220 E:236 ||| JJ
studies ||| S:236 E:243 ||| NNS
.  ||| S:243 E:245 ||| .
Creating  ||| S:245 E:254 ||| VBG
such  ||| S:254 E:259 ||| JJ
studies  ||| S:259 E:267 ||| NNS
requires  ||| S:267 E:276 ||| VBZ
a  ||| S:276 E:278 ||| DT
significant  ||| S:278 E:290 ||| JJ
amount  ||| S:290 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
time  ||| S:300 E:305 ||| NN
and  ||| S:305 E:309 ||| CC
resources ||| S:309 E:318 ||| NNS
.  ||| S:318 E:320 ||| .
It  ||| S:320 E:323 ||| PRP
is  ||| S:323 E:326 ||| VBZ
therefore  ||| S:326 E:336 ||| RB
usual  ||| S:336 E:342 ||| JJ
to  ||| S:342 E:345 ||| TO
reuse  ||| S:345 E:351 ||| VB
the  ||| S:351 E:355 ||| DT
data  ||| S:355 E:360 ||| NNS
from  ||| S:360 E:365 ||| IN
one  ||| S:365 E:369 ||| CD
study  ||| S:369 E:375 ||| NN
for  ||| S:375 E:379 ||| IN
several  ||| S:379 E:387 ||| JJ
research  ||| S:387 E:396 ||| NN
projects ||| S:396 E:404 ||| NNS
.  ||| S:404 E:406 ||| .
Often  ||| S:406 E:412 ||| RB
each  ||| S:412 E:417 ||| DT
project  ||| S:417 E:425 ||| NN
requires  ||| S:425 E:434 ||| VBZ
implementing  ||| S:434 E:447 ||| VBG
new  ||| S:447 E:451 ||| JJ
analysis  ||| S:451 E:460 ||| NN
code ||| S:460 E:464 ||| NN
,  ||| S:464 E:466 ||| ,
integration  ||| S:466 E:478 ||| NN
with  ||| S:478 E:483 ||| IN
specific  ||| S:483 E:492 ||| JJ
knowledge  ||| S:492 E:502 ||| NN
bases ||| S:502 E:507 ||| NNS
,  ||| S:507 E:509 ||| ,
and  ||| S:509 E:513 ||| CC
specific  ||| S:513 E:522 ||| JJ
visualizations ||| S:522 E:536 ||| NN
.  ||| S:536 E:538 ||| .
Although  ||| S:538 E:547 ||| IN
existing  ||| S:547 E:556 ||| VBG
data  ||| S:556 E:561 ||| NNS
exploration  ||| S:561 E:573 ||| NN
tools  ||| S:573 E:579 ||| NNS
are  ||| S:579 E:583 ||| VBP
available  ||| S:583 E:593 ||| JJ
for  ||| S:593 E:597 ||| IN
single  ||| S:597 E:604 ||| JJ
study  ||| S:604 E:610 ||| NN
data  ||| S:610 E:615 ||| NNS
exploration ||| S:615 E:626 ||| NN
,  ||| S:626 E:628 ||| ,
no  ||| S:628 E:631 ||| DT
tool  ||| S:631 E:636 ||| NN
provides  ||| S:636 E:645 ||| VBZ
all  ||| S:645 E:649 ||| PDT
the  ||| S:649 E:653 ||| DT
required  ||| S:653 E:662 ||| JJ
functionality  ||| S:662 E:676 ||| NN
for  ||| S:676 E:680 ||| IN
multistudy  ||| S:680 E:691 ||| JJ
data  ||| S:691 E:696 ||| NN
exploration ||| S:696 E:707 ||| NN
.  ||| S:707 E:709 ||| .
We  ||| S:709 E:712 ||| PRP
have  ||| S:712 E:717 ||| VBP
therefore  ||| S:717 E:727 ||| RB
used  ||| S:727 E:732 ||| VBN
the  ||| S:732 E:736 ||| DT
Kvik  ||| S:736 E:741 ||| JJ
framework  ||| S:741 E:751 ||| NN
to  ||| S:751 E:754 ||| TO
develop  ||| S:754 E:762 ||| VB
Kvik  ||| S:762 E:767 ||| NNP
Pathways ||| S:767 E:775 ||| NNP
,  ||| S:775 E:777 ||| ,
an  ||| S:777 E:780 ||| DT
application  ||| S:780 E:792 ||| NN
for  ||| S:792 E:796 ||| IN
exploring  ||| S:796 E:806 ||| VBG
gene  ||| S:806 E:811 ||| NN
expression  ||| S:811 E:822 ||| NN
data  ||| S:822 E:827 ||| NNS
in  ||| S:827 E:830 ||| IN
the  ||| S:830 E:834 ||| DT
context  ||| S:834 E:842 ||| NN
of  ||| S:842 E:845 ||| IN
biological  ||| S:845 E:856 ||| JJ
pathways ||| S:856 E:864 ||| NN
.  ||| S:864 E:866 ||| .
We  ||| S:866 E:869 ||| PRP
have  ||| S:869 E:874 ||| VBP
used  ||| S:874 E:879 ||| VBN
Kvik  ||| S:879 E:884 ||| NNP
Pathways  ||| S:884 E:893 ||| NNP
to  ||| S:893 E:896 ||| TO
explore  ||| S:896 E:904 ||| VB
data  ||| S:904 E:909 ||| NNS
from  ||| S:909 E:914 ||| IN
both  ||| S:914 E:919 ||| PDT
a  ||| S:919 E:921 ||| DT
cross-sectional  ||| S:921 E:937 ||| JJ
study  ||| S:937 E:943 ||| NN
design  ||| S:943 E:950 ||| NN
and  ||| S:950 E:954 ||| CC
a  ||| S:954 E:956 ||| DT
case-control  ||| S:956 E:969 ||| JJ
study  ||| S:969 E:975 ||| NN
within  ||| S:975 E:982 ||| IN
the  ||| S:982 E:986 ||| DT
Norwegian  ||| S:986 E:996 ||| JJ
Women  ||| S:996 E:1002 ||| NNS
and  ||| S:1002 E:1006 ||| CC
Cancer  ||| S:1006 E:1013 ||| NNP
( ||| S:1013 E:1014 ||| -LRB-
NOWAC ||| S:1014 E:1019 ||| NNP
)  ||| S:1019 E:1021 ||| -RRB-
cohort ||| S:1021 E:1027 ||| NN
.  ||| S:1027 E:1029 ||| .
Kvik  ||| S:1029 E:1034 ||| NNP
Pathways  ||| S:1034 E:1043 ||| NNP
follows  ||| S:1043 E:1051 ||| VBZ
the  ||| S:1051 E:1055 ||| DT
three-tier  ||| S:1055 E:1066 ||| JJ
architecture  ||| S:1066 E:1079 ||| NN
in  ||| S:1079 E:1082 ||| IN
web  ||| S:1082 E:1086 ||| JJ
applications  ||| S:1086 E:1099 ||| NNS
using  ||| S:1099 E:1105 ||| VBG
a  ||| S:1105 E:1107 ||| DT
powerful  ||| S:1107 E:1116 ||| JJ
back-end  ||| S:1116 E:1125 ||| JJ
for  ||| S:1125 E:1129 ||| IN
statistical  ||| S:1129 E:1141 ||| JJ
analyses  ||| S:1141 E:1150 ||| NNS
and  ||| S:1150 E:1154 ||| CC
retrieval  ||| S:1154 E:1164 ||| NN
of  ||| S:1164 E:1167 ||| IN
metadata.In  ||| S:1167 E:1179 ||| CD
this  ||| S:1179 E:1184 ||| DT
note ||| S:1184 E:1188 ||| NN
,  ||| S:1188 E:1190 ||| ,
we  ||| S:1190 E:1193 ||| PRP
describe  ||| S:1193 E:1202 ||| VBP
how  ||| S:1202 E:1206 ||| WRB
we  ||| S:1206 E:1209 ||| PRP
used  ||| S:1209 E:1214 ||| VBD
the  ||| S:1214 E:1218 ||| DT
Kvik  ||| S:1218 E:1223 ||| JJ
framework  ||| S:1223 E:1233 ||| NN
to  ||| S:1233 E:1236 ||| TO
develop  ||| S:1236 E:1244 ||| VB
the  ||| S:1244 E:1248 ||| DT
Kvik  ||| S:1248 E:1253 ||| NNP
Pathways  ||| S:1253 E:1262 ||| NNP
application ||| S:1262 E:1273 ||| NN
.  ||| S:1273 E:1275 ||| .
Kvik  ||| S:1275 E:1280 ||| NNP
Pathways  ||| S:1280 E:1289 ||| NNP
was  ||| S:1289 E:1293 ||| VBD
used  ||| S:1293 E:1298 ||| VBN
by  ||| S:1298 E:1301 ||| IN
our  ||| S:1301 E:1305 ||| PRP$
team  ||| S:1305 E:1310 ||| NN
of  ||| S:1310 E:1313 ||| IN
epidemiologists  ||| S:1313 E:1329 ||| JJ
toexplore  ||| S:1329 E:1339 ||| JJ
gene  ||| S:1339 E:1344 ||| NN
expression  ||| S:1344 E:1355 ||| NN
data  ||| S:1355 E:1360 ||| NNS
from  ||| S:1360 E:1365 ||| IN
healthy  ||| S:1365 E:1373 ||| JJ
women  ||| S:1373 E:1379 ||| NNS
with  ||| S:1379 E:1384 ||| IN
high  ||| S:1384 E:1389 ||| JJ
and  ||| S:1389 E:1393 ||| CC
low  ||| S:1393 E:1397 ||| JJ
plasma  ||| S:1397 E:1404 ||| NN
ratios  ||| S:1404 E:1411 ||| NNS
of  ||| S:1411 E:1414 ||| IN
essential  ||| S:1414 E:1424 ||| JJ
fatty  ||| S:1424 E:1430 ||| JJ
acids ||| S:1430 E:1435 ||| NNS
.  ||| S:1435 E:1437 ||| .
